CAM
CADL icon

Close Asset Management’s Candel Therapeutics CADL Stock Holding History

Close Asset Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14K Hold
1,350
– – ﹤0.01% 214
2026
Q1 		$7K Hold
1,350
– – ﹤0.01% 237
2025
Q4 		$8K Hold
1,350
– – ﹤0.01% 234
2025
Q3 		$7K Hold
1,350
– – ﹤0.01% 237
2025
Q2 		$7K Buy
+1,350
New +$6.95K ﹤0.01% 225

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Close Asset Management's CADL Position: Q2 2026 in Review

Close Asset Management held its Candel Therapeutics (CADL) position steady in Q2 2026 at 1,350 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #214.

Close Asset Management first reported a position in CADL in Q2 2025 and has held it in 5 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Close Asset Management held 1,350 shares of Candel Therapeutics worth $14K as of Q2 2026.
  • Close Asset Management left its Candel Therapeutics share count unchanged in Q2 2026.
  • Candel Therapeutics made up ﹤0.01% of Close Asset Management's portfolio in Q2 2026, its #214 holding.
  • Close Asset Management first reported a position in Candel Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Close Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.